We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+9.63%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.56B
AUM Growth
-$122M
Cap. Flow
-$69.5M
Cap. Flow %
-4.44%
Top 10 Hldgs %
64.55%
Holding
66
New
15
Increased
13
Reduced
12
Closed
14

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$46.2M
2
ISRG icon
Intuitive Surgical
ISRG
+$36.9M
3
BIIB icon
Biogen
BIIB
+$36.7M
4
MRK icon
Merck
MRK
+$25.7M
5
PTCT icon
PTC Therapeutics
PTCT
+$23.6M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$95.2M
2
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$74.6M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$57.4M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$45.3M
5
AZN icon
AstraZeneca
AZN
+$41.6M

Sector Composition

Rank Sector Weight
1 Healthcare 93.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$322M 20.6%
1,773,124
-300,000
-14% -$57.4M
NTRA icon
2
Natera
NTRA
$37.5B
$172M 11.01%
3,100,560
– –
MRK icon
3
Merck
MRK
$324B
$89.5M 5.73%
841,522
+238,166
+39% +$25.7M
SPY icon
4
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$81.9M 5.24%
+200,000
New +$79.8M
ASND icon
5
Ascendis Pharma A/S
ASND
$16.7B
$80.8M 5.17%
754,032
-126,768
-14% -$14.5M
JBIO
6
Jade Biosciences
JBIO
$1.22B
$75.8M 4.85%
107,391
– –
RETA
7
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$57.1M 3.65%
627,683
-364,346
-37% -$21.4M
LLY icon
8
Eli Lilly
LLY
$1.07T
$47.1M 3.01%
+137,100
New +$46.2M
HZNP
9
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$44.6M 2.85%
408,819
-4,354
-1% -$481K
ISRG icon
10
Intuitive Surgical
ISRG
$121B
$38.2M 2.44%
+149,589
New +$36.9M
BIIB icon
11
Biogen
BIIB
$29.9B
$36.9M 2.36%
+132,600
New +$36.7M
BMRN icon
12
BioMarin Pharmaceuticals
BMRN
$11.5B
$34.9M 2.23%
359,035
-35,608
-9% -$3.69M
DXCM icon
13
DexCom
DXCM
$27.6B
$29.9M 1.91%
257,227
+116,549
+83% +$13M
TVTX icon
14
Travere Therapeutics
TVTX
$5.33B
$28.4M 1.82%
1,263,721
+685,453
+119% +$14.6M
VERA icon
15
Vera Therapeutics
VERA
$2.54B
$26.9M 1.72%
3,467,156
+285,714
+9% +$2.21M
PTCT icon
16
PTC Therapeutics
PTCT
$6.37B
$25M 1.6%
+517,095
New +$23.6M
ZNTL icon
17
Zentalis Pharmaceuticals
ZNTL
$308M
$24.8M 1.58%
1,439,062
+435,017
+43% +$8.81M
INBX
18
DELISTED
Inhibrx, Inc. Common Stock
INBX
$23.5M 1.5%
1,244,488
+134,305
+12% +$3.12M
KDNY
19
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$23.2M 1.48%
1,002,348
+195,889
+24% +$4.67M
SNDX icon
20
Syndax Pharmaceuticals
SNDX
$1.84B
$22.7M 1.45%
1,075,424
+372,350
+53% +$9.26M
ISEE
21
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$22M 1.41%
905,982
+267,584
+42% +$5.86M
IMTX icon
22
Immatics
IMTX
$1.24B
$21.6M 1.38%
3,132,694
+1,131,918
+57% +$9.27M
INZY
23
DELISTED
Inozyme Pharma
INZY
$20.9M 1.34%
3,655,308
– –
GERN icon
24
Geron
GERN
$911M
$18M 1.15%
8,274,892
+6,815,303
+467% +$19.4M
SRPT icon
25
Sarepta Therapeutics
SRPT
$1.66B
$16.4M 1.05%
119,065
-128,890
-52% -$16.7M
1
2 3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2023 Portfolio in Review

As of Q1 2023, Sofinnova Investments held 66 positions worth $1.56B, down 7.2% from $1.69B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Sofinnova Investments withdrew a net $69.5M in Q1 2023, closing 14 positions and reducing 12 holdings. Its most notable exit was Sanofi, an estimated $95.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 98% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Eli Lilly worth $47.1M.

  • Sofinnova Investments's largest Q1 2023 buy was Eli Lilly: 137,100 shares worth $47.1M.
  • Sofinnova Investments added most to Merck in Q1 2023, an estimated $25.7M increase.
  • Sofinnova Investments's biggest Q1 2023 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $57.4M.
  • Sofinnova Investments fully exited Sanofi in Q1 2023, selling an estimated $95.2M.
  • Sofinnova Investments's ten largest holdings make up 65% of its $1.56B portfolio in Q1 2023.
  • Sofinnova Investments opened 15 new positions and closed 14 in Q1 2023.
  • Sofinnova Investments's portfolio value fell 7.2% quarter-over-quarter to $1.56B.

Based on Sofinnova Investments's 13F filing for Q1 2023, filed 11 May 2023.